PDS Biotechnology Corp files 8-K covering a debt obligation
The Nasdaq-listed pharmaceutical company filed an 8-K dated 2026-09-04 that includes debt-related disclosures.
PDS Biotechnology Corp, a Delaware-incorporated pharmaceutical preparations company traded on Nasdaq under the ticker PDSB, filed a Form 8-K on 2026-09-04.[1][2]
The filing, under accession number 0001140361-26-035809, includes Items 1.01, 2.03, and 9.01 and lists an 8-K document as the matched filing.[1]
The 8-K carries a period ending of 2026-08-31.[1]
The filing was submitted through the sec_edgar_debt source with CIK 0001472091.[1][2]
Earlier, on 2026-08-25, a restructuring announcement was recorded for the company.[3]